How SGLT2 Inhibitors Have Changed the Management of Chronic Kidney Disease
Laura E. Berall, MD, MSc, FRCPC
Topics: Kidney Disease, SGLT2 Inhibitors
Details
Objectives
- To review the mechanism of action of SGLT2i in non-diabetic CKD.
- To identify patients who would be the most likely to benefit from initiation of SGLT2i.
- To recognize how SGLT2i fit into current treatment algorithms for non-diabetic CKD.
- To appreciate the risks of adding SGLT2 inhibitors.
Faculty
Laura E. Berall MD, MSc, FRCPC
Laura E. Berall, MD, MSc, FRCPC received her Doctor of Medicine degree at Western University followed by her Internal Medicine residency and Nephrology fellowship at the University of Toronto. She went on to complete additional fellowships in Glomerular Disease as well as Pregnancy and Nephrology, while simultaneously completing a Master of Science degree in Quality Improvement and Patient Safety. She works as a staff nephrologist at Humber River Hospital (HRH), where she leads both the Glomerulonephritis Clinic as well as the Pregnancy and Nephrology Clinic. She serves on the Canadian Society of Nephrology's Quality Improvement Committee, HRH's Medical Quality Improvement Committee and the HRH Physicians IT Advisory Committee. Her research interests include: quality improvement, glomerulonephritis, and pregnancy and kidney disease.